Azitra, Inc. reported its financial results for the third quarter and the nine months ended September 30, 2025, revealing a continued lack of revenue and significant operational losses. The company recorded no service revenue during the third quarter, maintaining a total revenue of $0 for the nine-month period, a decrease from $7,500 in the same period last year. Operating expenses for the third quarter were approximately $2.77 million, a slight decrease of 5% compared to $2.93 million in the prior year. For the nine months ended September 30, 2025, total operating expenses rose to $8.74 million, up 2% from $8.56 million in the same period of 2024. The net loss attributable to common shareholders for the third quarter was $2.76 million, a 174% increase from the $1.01 million loss reported in the same quarter of 2024.
The company’s financial position has deteriorated compared to the previous fiscal period, with total assets decreasing to $4.3 million from $7.36 million at the end of 2024. Cash and cash equivalents also fell significantly, from $4.55 million at the end of 2024 to $1.40 million as of September 30, 2025. Azitra's accumulated deficit has increased to $66.29 million, reflecting ongoing operational challenges and the need for additional funding to support its clinical development programs.
Strategically, Azitra has been active in raising capital through various public offerings and an equity line of credit (ELOC) with Alumni Capital LP. The company completed several follow-on offerings, raising approximately $6 million in total gross proceeds from these initiatives. However, the company has also faced compliance issues with the NYSE American, receiving a deficiency letter indicating that it does not meet the required stockholders' equity of at least $4 million due to reported losses. Azitra has submitted a plan to regain compliance, but there is no assurance that it will be accepted.
Operationally, Azitra is focused on advancing its clinical programs, particularly its lead candidates ATR-12 and ATR-04, which are in various stages of clinical trials. The company has reported initial safety results for ATR-12 and has begun dosing patients for ATR-04. Despite these advancements, the company has indicated that it will require significant additional funding to continue its operations and complete the development of its product candidates. The management has expressed concerns about the company's ability to continue as a going concern, emphasizing the need for further financing to support ongoing operations and clinical trials.
Looking ahead, Azitra plans to continue its focus on developing innovative therapies for precision dermatology, leveraging its proprietary microbial library and partnerships with academic institutions. However, the company acknowledges the substantial risks associated with its business model, including the need for ongoing funding and the potential for delays in clinical development. The outlook remains uncertain as the company navigates these challenges while striving to achieve its strategic objectives.
About Azitra, Inc.
Azitra, Inc. is a clinical-stage biopharmaceutical company developing precision dermatology therapies using engineered proteins and live biotherapeutic products derived from a proprietary microbial library of over 1,500 bacterial strains. Focusing on genetically engineered Staphylococcus epidermidis, Azitra creates topical treatments targeting rare and chronic skin diseases, leveraging AI-driven strain screening and licensed genetic engineering technologies to deliver therapeutic proteins directly into the skin for improved disease management.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.